Your browser doesn't support javascript.
loading
Endometrial cancer prognosis in women with endometriosis and adenomyosis: A retrospective nationwide cohort study of 40 840 women.
Hermens, Marjolein; van Altena, Anne M; van der Aa, Maaike; Bulten, Johan; van Vliet, Huib A A M; Siebers, Albert G; Bekkers, Ruud L M.
Afiliação
  • Hermens M; Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, The Netherlands.
  • van Altena AM; Department of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van der Aa M; Department of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Bulten J; Department of Research, Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
  • van Vliet HAAM; Department of Obstetrics and Gynecology, University Hospital, Belgium, Ghent.
  • Siebers AG; Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, The Netherlands.
  • Bekkers RLM; Department of Obstetrics and Gynecology, University Hospital, Belgium, Ghent.
Int J Cancer ; 150(9): 1439-1446, 2022 05 01.
Article em En | MEDLINE | ID: mdl-34921730
ABSTRACT
We aim to compare endometrial cancer survival in women with or without histological proven endometriosis or adenomyosis. We identified all women with endometrial cancer between 1990 and 2015 from the Netherlands Cancer Registry (NCR). Data were linked to the Dutch pathology database (PALGA) to select all women with histological proven endometriosis/adenomyosis. Overall survival was compared between women with endometrial cancer with or without endometriosis/adenomyosis. We used multivariable Cox proportional hazard analysis to estimate hazard ratios (HRs). We included 1701 women with endometrial cancer and endometriosis/adenomyosis, of whom 1236 (72.7%) women had adenomyosis, 320 (18.8%) had endometriosis and 145 (8.5%) had both. We compared these women to 39 139 women with endometrial cancer without endometriosis/adenomyosis. Women in the combined endometriosis/adenomyosis cohort were younger at endometrial cancer diagnosis, had earlier disease stage, more often had endometrioid endometrial cancer and low grade tumors. The 5-year survival rate in the combined endometriosis/adenomyosis cohort was 84.8% (95% CI 84.6-88.1) and 71.6% (95% CI 71.1-72.0) in the nonendometriosis/adenomyosis cohort. Univariable analysis resulted in a crude HR of 0.63 (95% CI 0.59-0.69). Significant confounding factors were age, stage, cancer subtype, histological grading, surgery and chemotherapy rate. Correction for these confounders resulted in a HR of 0.98 (95% CI 0.90-1.06). Including endometriosis/adenomyosis status as a categorical factor resulted in similar HRs. In conclusion, women with endometrial cancer and histologically proven endometriosis/adenomyosis have a better overall survival when compared to women with endometrial cancer without endometriosis/adenomyosis. This better survival was correlated to stage, grade, age and histological subtype, but not to the presence of endometriosis/adenomyosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Endometriose / Adenomiose Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Endometriose / Adenomiose Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article